- Revvity, Inc., headquartered in Waltham, Massachusetts, specializes in medical products and equipment, focusing on AI-enabled solutions for oncology and biologics research workflows.
- In April 2026, Revvity launched its Signals BioDesign molecular cloning software and showcased new high-impact discovery platforms at industry conferences, aiming to streamline drug discovery processes.
- The company serves a diverse clientele, including pharmaceutical and biotech firms, and has recently attracted attention for its innovative tools designed to enhance research efficiency in cancer studies.
- Revvity's ideal buyers are R&D teams within biotech and pharmaceutical companies looking to reduce workflow friction and improve research outcomes, making their recent product launches particularly timely for addressing current market needs.
Revvity's workforce is organized into 17 departments, with a notable concentration in Operations, Community and Social Services, and Information Technology, which collectively account for a significant portion of the total headcount. Operations leads with 157 employees, followed closely by Community and Social Services at 141 and Information Technology with 103. This distribution reflects a balanced focus on both operational efficiency and technological advancement, essential for the medical products and equipment industry.
The company operates across 130 locations, with a strong presence in Waltham, MA, housing 101 employees, followed by Boston, MA, with 50 employees. Other notable locations include San Diego, CA, and Salem, MA, with 26 and 22 employees respectively. The 'Other' category, comprising 629 employees, indicates a distributed workforce, suggesting Revvity's strategic approach to geographic diversification while maintaining a concentrated operational base in Massachusetts.
